Washington, DC - February 13, 2015 - According to a multinational clinical trial involving nearly 20,000 young women, the human papilloma virus vaccine, Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18, which are responsible for about 70 percent of all cases. That effectiveness endured for the study’s entire follow-up, of up to four years. The research was published February 4 in Clinical and Vaccine Immunology, a journal of the American Society for Microbiology.
WASHINGTON, DC - FEBRUARY 11, 2015 -- With minor tinkering, a peptide—a tiny protein—from the skin of a frog could be fashioned into a novel antibiotic that would lack the toxic byproducts of some more conventional drugs. More importantly, such peptides would represent a new class of antibiotics, at a time when new classes are sorely needed as resistance rises among existing classes. The research was published online, 26 January 2015, in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.